EX-23.2 3 blph-20210611ex232ab3850.htm EX-23.2

Exhibit 23.2

Consent of Independent Registered Public Accounting Firm

The Board of Directors

Bellerophon Therapeutics, Inc.:


We consent to the use of our report incorporated by reference herein.

/s/ KPMG LLP

Short Hills, New Jersey

June 11, 2021